tiprankstipranks
Angion Biomedica (ANGN)
NASDAQ:ANGN

Angion Biomedica Stock Analysis & Ratings

ANGN Stock Chart & Stats

Day’s Range$1.26 - $1.371
52-Week Range$1.22 - $16.26
Previous Close$1.3
Volume90.94K
Average Volume (3M)90.41K
Market Cap$38.95M
P/E Ratio-0.6
Beta0.40
Next EarningsAug 11, 2022
EPS ForecastN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score3
EPS (TTM)-2.16


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

ANGN FAQ

What was Angion Biomedica’s price range in the past 12 months?
Angion Biomedica lowest stock price was $1.22 and its highest was $16.26 in the past 12 months.
    What is Angion Biomedica’s market cap?
    Angion Biomedica’s market cap is $38.95M.
      What is Angion Biomedica’s price target?
      The average price target for Angion Biomedica is $32.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $32.00 ,the lowest forecast is $32.00. The average price target represents 2361.54% Increase from the current price of $1.3.
        What do analysts say about Angion Biomedica?
        Angion Biomedica’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
          When is Angion Biomedica’s upcoming earnings report date?
          Angion Biomedica’s upcoming earnings report date is Aug 11, 2022 which is in 86 days.
            How were Angion Biomedica’s earnings last quarter?
            Angion Biomedica released its earnings results on May 16, 2022. The company reported -$0.48 earnings per share for the quarter, missing the consensus estimate of -$0.435 by -$0.045.
              Is Angion Biomedica overvalued?
              According to Wall Street analysts Angion Biomedica’s price is currently Undervalued.
                Does Angion Biomedica pay dividends?
                Angion Biomedica does not currently pay dividends.
                What is Angion Biomedica’s EPS estimate?
                Angion Biomedica’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Angion Biomedica have?
                Angion Biomedica has 29,960,000 shares outstanding.
                  What happened to Angion Biomedica’s price movement after its last earnings report?
                  Angion Biomedica reported an EPS of -$0.48 in its last earnings report, missing expectations of -$0.435. Following the earnings report the stock price went same 0%.
                    Which hedge fund is a major shareholder of Angion Biomedica?
                    Currently, no hedge funds are holding shares in ANGN

                    ---

                    Angion Biomedica Stock Analysis

                    Smart Score
                    3
                    Underperform
                    1
                    2
                    3
                    4
                    5
                    6
                    7
                    8
                    9
                    10
                    Price Target
                    $32.00
                    ▲(2361.54% Upside)
                    Moderate Buy
                    The Angion Biomedica stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                    Learn more about TipRanks Smart Score

                    Company Description

                    Angion Biomedica

                    Angion Biomedica Corp was incorporated in the State of Delaware on April 6. 1998. It is a clinical stage biopharmaceutical company. The Company discovers and develops novel therapeutic agents to treat acute and chronic organ injury by harnessing the body's protective, reparative and regenerative systems. It is developing therapeutics for both orphan indications and large clinical markets of unmet medical need.

                    ---
                    Similar Stocks
                    No data currently available

                    Popular Stocks

                    ---
                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis